J&J Bounces Back In Q3, Led By Interventional Devices
Johnson & Johnson’s worldwide medical device revenues grew about 50% sequentially in the third quarter to $6.2bn.
You may also be interested in...
J&J expects its medical device sales to begin growing rapidly by the middle of 2021 as the pandemic subsides.
Boston Scientific’s management believes the ongoing recovery of procedure volumes and new technology will allow it to show revenue growth in the fourth quarter.
It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.